Skip to main content
Genscript Biotech Corporation logo

Genscript Biotech Corporation — Investor Relations & Filings

Ticker · 1548 ISIN · KYG3825B1059 LEI · 529900YIYUOJOXSAE372 HKEX Manufacturing
Open in API
Filings indexed 819 across all filing types
Latest filing 2025-04-16 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1548

About Genscript Biotech Corporation

http://www.genscript.com/investor-relat…

Genscript Biotech Corporation is a world-leading technology and service provider specializing in life science research and manufacturing. The company offers a comprehensive portfolio of services and products essential for fundamental life science research, translational biomedical research, and early drug discovery and development. Core offerings include custom synthesis of genes, peptides, proteins, and antibodies, alongside molecular cloning and oligonucleotide production. GenScript also provides Contract Development and Manufacturing Organization (CDMO) solutions for innovative therapies through its specialized subsidiaries. The corporation leverages biotechnology and AI-driven approaches to advance life science solutions.

Recent filings

Filing Released Lang Actions
(REVISED) Next Day Disclosure Returns
Share Issue/Capital Change Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed by Genscript Biotech Corporation under the Hong Kong Stock Exchange listing rules to report changes in issued shares due to the exercise of share options. It is a regulatory announcement of a share issuance event (new shares issued under a share scheme). This falls squarely under the “Share Issue/Capital Change” category.
2025-04-16 English
VOLUNTARY ANNOUNCEMENT: LEGEND BIOTECH ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 31 MARCH 2025
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement filed on the Hong Kong Exchange providing preliminary sales figures for a product for the quarter ended March 31, 2025. It is not a full earnings release (no comprehensive income statement or EPS data), not an annual or interim report, and not a notice of dividends or board changes. It’s a typical regulatory update announcement, falling into the general “Regulatory Filings” category (RNS) as it does not fit any more specific classification.
2025-04-15 English
Next Day Disclosure Returns
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) reporting changes in issued shares due to the exercise of share options. It details the issuance of new ordinary shares (5,120,000 shares) and updates to the issuer’s total share capital. This falls squarely under announcements of new share issues or capital changes rather than repurchases or general regulatory notices. Therefore, it should be classified as a Share Issue/Capital Change (SHA).
2025-04-14 English
Notification Letter to Non-Registered Shareholders and Reply Form - Reminder letter regarding the arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 1% confidence The document is a reminder letter notifying non-registered shareholders of the electronic dissemination arrangement for all future corporate communications and providing instructions for requesting printed copies. It does not present any financial results, audit findings, or substantive meeting materials such as an annual report, proxy statement, or AGM presentation. It is a miscellaneous regulatory notification about corporate communications distribution rather than a formal report or solicitation. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2025-04-08 English
Notification Letter to Registered Shareholders and Reply Form - Reminder letter regarding the arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 0% confidence The document is not an annual or interim financial report, earnings release, proxy statement, board change announcement, or any other specific category. Instead, it is a routine shareholder letter reminding register holders about the electronic dissemination arrangement for corporate communications and includes a reply form. It does not constitute publication of a specific report (RPA) nor a vote solicitation (PSI). It therefore falls under the general regulatory announcements fallback category: RNS.
2025-04-08 English
FORM OF PROXY FOR 2025 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a "Form of Proxy" for the 2025 Annual General Meeting of Genscript Biotech Corporation, used to solicit shareholder votes and appoint proxies. This falls under the definition of "Proxy Solicitation & Information Statement" (PSI). It is not a full AGM presentation (AGM-R), nor a notice or summary of results, but the actual proxy solicitation material.
2025-04-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.